source
- Option-to-acquire structures stay uncommon amid biotech's busy M&A seasonBiotech companies are experiencing one of the busiest deal-making years on record, with a flood of announced mergers and acquisitions. Two recent transactions have highlighted the option-to-acquir…
- Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drugSpruce Biosciences has taken another step toward filing for FDA approval of its ultra-rare disease drug candidate, ticking off some of the manufacturing tasks needed to submit the long-awaited appl…Fierce Biotech · 11h ago↗ source